Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Mol Cancer Res. 2014 Jan 24;12(4):514–526. doi: 10.1158/1541-7786.MCR-13-0505

Figure 2.

Figure 2

FAK inhibition with siRNA in G401 and SK-NEP-1 human renal tumor cell lines. G401 and SK-NEP-1 cells were treated with HiPerFect® alone (control), negative control siRNA (siNeg), or siRNA specific for FAK (siFAK, 20, 40, 60 nM) for 24 hours. A. Immunoblotting for FAK showed decreased FAK expression in the G401 cells with 20 nM siFAK and in the SK-NEP-1 cells with 40 nM siFAK. Treatment with siNeg did not affect FAK expression. B. G401 and SK-NEP-1 cells were treated with siFAK for 24 hours (20 nM and 40 nM, respectively), cellular viability was measured using trypan blue exclusion, and reported as fold change in viability. In both cell lines, viability decreased significantly following treatment with siFAK. Cell viability was not affected by the siNeg treatment. Experiments were repeated at least in triplicate and data reported as mean fold change ± SEM. C. G401 and SK-NEP-1 cells were treated with increasing doses of siFAK for 24 hours and lysates examined with immunoblotting for PARP cleavage products. Increasing amounts of siFAK led to PARP cleavage, indicating apoptosis. siNeg did not result in PARP cleavage in either cell line.